Abstract: Provided is a method of producing various 2-((meth)allyloxymethyl)acrylic acid derivatives in high yields with no need to load a raw material in a large excess for improving a reaction conversion ratio, and without use of a catalyst having high toxicity or a strong acid catalyst. Also provided are powder compounds that may be utilized as raw materials for synthesizing various chemical products. A method of producing a 2-((meth)allyloxymethyl)acrylic acid derivative includes causing the powder of a salt of a 2-((meth)allyloxymethyl)acrylic acid anion and an alkali metal cation (component A), and a halide (component B) to react with each other to produce a 2-((meth)allyloxymethyl)acrylic acid derivative. The 2-((meth)allyloxymethyl)acrylic acid alkali metal salt powder is the powder of a salt of a 2-((meth)allyloxymethyl)acrylic acid anion and an alkali metal cation, and has a bulk density of 0.50 g/mL or more, or a water content of 0.05 wt % or less.

Abstract: The present disclosure provides methods and compositions for inhibiting degradation of dimethyl trisulfide (DMTS) in solution. Concentrate compositions include DMTS and polar inorganic or organic solvent. The compositions can be stored in containers for at least 2 weeks at 54° C. or at least one year at room temperature and less than 50% of the DMTS degrades. The concentrate compositions can be diluted for use and combined with other components to form various solutions.

Abstract: The present disclosure is directed to provide a vinylsulfonic anhydride which is useful as a synthetic intermediate for synthesis of a fluorinated monomer. It is also directed to efficiently produce the vinylsulfonic anhydride. It is further directed to efficiently produce a fluorinated monomer using the vinylsulfonic anhydride. A vinylsulfonic anhydride of the present disclosure is expressed by the general formula (1). Further, a process for producing a vinylsulfonic anhydride of the present disclosure includes making a vinylsulfonic acid compound represented by the general formula (2) come in contact and be mixed with an anhydridization agent.

Abstract: The present invention relates to a process for preparing a mixture M1 of enol phosphate isomers devoid of (E,E) isomer and comprising at least 98% of (E,Z) isomer, at least 0.1% of (Z,Z) isomer and at least 0.1% of (Z,E) isomer, comprising bringing a mixture of isomers of said enol phosphate comprising a detectable amount of (E,E) isomer into contact with a hydrolysable dienophile in an organic solvent, followed by base hydrolysis of the medium obtained and elimination of the adduct formed, in order to obtain the mixture M1 devoid of (E,E) isomer.

Abstract: A method for preparing amantadine includes chlorinating adamantane with chlorine gas in a solvent in the presence of a Lewis acid catalyst to obtain a reaction liquid, and then removing the solvent and residues containing the catalyst in the reaction liquid, to obtain a chlorinated product. The chlorinated product is mixed with urea to a mixture, and the mixture is subjected to an amination reaction, to obtain amantadine. The results of examples show that the purity of the prepared amantadine could reach 99.5% or more.

Abstract: The current invention relates to long ?-? di-functional linear molecules as building blocks closing the gap between small molecules and polymers, or in a polycondensated form, in the production of oligomers and/or polymers, surfactants, lubricants, coatings, colloidal stabilizing surface chains/molecules.

Abstract: A diphenylsulfone compound containing 4,4?-dihydroxydiphenylsulfone is produced in good yield in a short time and at a relatively low temperature. A diphenylsulfone compound represented by formula (2) below is produced by irradiating, with microwaves, a compound represented by formula (1) below and a sulfonating agent so that a dehydration condensation reaction is carried out.

Abstract: The present invention provides for methyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt, a novel process for the preparation of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.

Abstract: Disclosed is a method of synthesizing a (1R,2R)-nitroalcohol compound of formula (I), as shown in the following reaction scheme, including: subjecting a compound of formula (II) and a compound of formula (III) to a condensation reaction in an organic solvent in the presence of a copper complex generated in situ from a chiral (1S,2R)-amino alcohol ligand and a cupric salt to produce the (1R,2R)-nitroalcohol compound of formula (I), where R1 and R2 are defined in the same manner as that in the specification. The method involves mild reaction conditions, excellent diastereoselectivity and high chemical yield, and thus it is suitable for industrial applications.

Abstract: A raw material for forming a thin film, comprising a compound represented by General Formula (1) below. wherein R1 represents an isopropyl group, R2 represents a methyl group, R3 and R4 each independently represent a linear or branched alkyl group having 1 to 5 carbon atoms, A represents a propane-1,2-diyl group and M represents copper, nickel, cobalt or manganese.

Abstract: The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

Abstract: The invention provides novel zwitterionic monomers and polymers (including copolymers) with pendent phosphonium-based zwitterionic moieties, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as surfactants, coatings, and interlayer materials, biomedical materials or agents.

Abstract: A method of preparing an ester by reacting a carboxylic acid with a (C1-C36)alcohol in the presence of a catalyst that is suitable for preparing carboxylic acid esters of monomeric carboxylic acids in high yield. The method reduces by-products of the reaction, in particular esters of dimeric, trimeric and/or oligomeric carboxylic acids. The method requires a minimal excess of alcohol and does not require removal of water and/or carboxylic acid ester from the reaction mixture. The method is particularly suitable for the reaction of hydroxyalkylcarboxylic acids and fatty alcohols.

Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

Abstract: Process for the production of methylidene malonates and cyanoacrylates employing in-situ formed iminium salts derived from acid halides and/or acid anhydrides and N,N,N?,N?-tetra hydrocarbyl diaminoalkanes, the acid halides and/or acid anhydrides being present in a molar excess relative to the diaminoalkanes, as co-reactants with select malonic acid esters and cyanoacetates, respectively.

Abstract: An embodiment relates to a substance comprising an end-capped amino compound comprising an amino compound and at least a portion of an end capping agent, wherein the at least the portion of the end capping agent contains no primary alkyl amine group and wherein the substance exhibits no activity as measured by: (a) a Cytotox CALUX assay; (b) a Steroidogenesis ER? CALUX assay; (c) a AR CALUX assay; (d) a Anti ERr? CALUX assay; (e) a Steroidogenesis AR CALUX assay; (f) an anti-AR CALUX assay; (g) a TR? CALUX assay; (h) a anti-TR? CALUX assay; (i) a TTR-TR? CALUX assay; or (j) a TPO assay.

Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.

Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.

Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.

Abstract: A process for preparing a 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl carboxylate compound of the following general formula (6), wherein R represents a monovalent hydrocarbon group having 1 to 9 carbon atoms, the process comprising esterifying a 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl compound of the following general formula (5), wherein X represents a hydroxyl group or a halogen atom, to form the 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl carboxylate compound (6).